A new study conducted by IU School of Medicine and to be presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy in Denver reports that an experimental vaccine for herpes simplex virus type 2, called GEN-003, can help reduce viral shedding. The vaccine has been developed by Genocea Biosciences of Cambridge, Mass.
"Typically vaccines do not modulate a disease someone already has contracted," said Fife, a professor of medicine and of microbiology and immunology. "The virus can be detected on the skin of people with genital herpes even when they are not having an outbreak. That is often how the disease is spread, often called viral shedding."
The injectable vaccine is given several times over the course of a few weeks. The clinical study is closed to enrollment, but participants continue to be followed. GEN-003 is one of the first vaccines intended to reduce the viral shedding and frequency and severity of outbreaks and transmission of herpes simplex virus type 2, which is the most common cause of genital herpes. It is estimated to infect more than 500 million people worldwide, and one out of six people age 14 to 49. In the U.S., an estimated 50-60 million people are affected.